Individualized prediction of illness course at the first psychotic episode: a support vector machine MRI study by Mourao-Miranda, J. et al.
Individualized prediction of illness course at the
ﬁrst psychotic episode: a support vector machine
MRI study
J. Mourao-Miranda
1,2, A. A. T. S. Reinders
3,4, V. Rocha-Rego
1, J. Lappin
3, J. Rondina
1, C. Morgan
3,
K. D. Morgan
3, P. Fearon
3, P. B. Jones
5, G. A. Doody
6, R. M. Murray
3, S. Kapur
3 and P. Dazzan
3,7*
1 Centre for Neuroimaging Sciences, Institute of Psychiatry, King’s College London, UK
2 Centre for Computational Statistics and Machine Learning, UCL, London, UK
3 Department of Psychosis Studies, Institute of Psychiatry, King’s College London, UK
4 Department of Neuroscience, University Medical Center Groningen, and BCN Neuroimaging Center, University of Groningen, The Netherlands
5 Department of Psychiatry, University of Cambridge, UK
6 Division of Psychiatry, University of Nottingham, UK
7 NIHR Biomedical Research Centre for Mental Health at the South London and Maudsley NHS Foundation Trust and Institute of Psychiatry,
King’s College London, UK
Background. To date, magnetic resonance imaging (MRI) has made little impact on the diagnosis and monitoring of
psychoses in individual patients. In this study, we used a support vector machine (SVM) whole-brain classiﬁcation
approach to predict future illness course at the individual level from MRI data obtained at the ﬁrst psychotic episode.
Method. One hundred patients at their ﬁrst psychotic episode and 91 healthy controls had an MRI scan. Patients
were re-evaluated 6.2 years (S.D.=2.3) later, and were classiﬁed as having a continuous, episodic or intermediate
illness course. Twenty-eight subjects with a continuous course were compared with 28 patients with an episodic
course and with 28 healthy controls. We trained each SVM classiﬁer independently for the following contrasts:
continuous versus episodic, continuous versus healthy controls, and episodic versus healthy controls.
Results. At baseline, patients with a continuous course were already distinguishable, with signiﬁcance above chance
level, from both patients with an episodic course (p=0.004, sensitivity=71, speciﬁcity=68) and healthy individuals
(p=0.01, sensitivity=71, speciﬁcity=61). Patients with an episodic course could not be distinguished from healthy
individuals. When patients with an intermediate outcome were classiﬁed according to the discriminating pattern
episodic versus continuous, 74% of those who did not develop other episodes were classiﬁed as episodic, and 65% of
those who did develop further episodes were classiﬁed as continuous (p=0.035).
Conclusions. We provide preliminary evidence of MRI application in the individualized prediction of future illness
course, using a simple and automated SVM pipeline. When replicated and validated in larger groups, this could
enable targeted clinical decisions based on imaging data.
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Introduction
The outcome of psychosis varies from recovery with
minimal symptoms to persistent psychosis with sub-
stantial cognitive and functional deﬁcits. Unfortu-
nately, there is no predictor that identiﬁes, at illness
onset, which patients will subsequently develop a
more severe illness course. Therefore, compared to
other areas of medicine, psychiatry lags behind in
terms of risk quantiﬁcation that could guide patients’
and clinicians’ choices.
In the past decades, brain structure has been inves-
tigated using magnetic resonance imaging (MRI) as a
potentialpredictorofoutcomeinpsychosis(vanHaren
et al. 2003, 2008). However, neuroanatomical changes
in psychosis are subtle and spatially distributed,
althoughpossiblymoremarkedintheadvancedillness
stages (Ellison-Wright et al. 2008; Bloemen et al. 2010).
As a result, the use of imaging has made little impact
in clinical practice on the diagnosis and monitoring of
psychoses in individual patients (Matthews et al.2006).
More recently, classiﬁcation methods have been
applied to structural imaging data with encouraging
results (Davatzikos et al. 2008; Kloppel et al. 2008;
Vemuri et al. 2008; Koutsouleris et al. 2009;
Karageorgiou et al. 2011; Kasparek et al. 2011). Among
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vector machine (SVM) is a pattern recognition tech-
nique that identiﬁes multivariate statistical properties
of the data that discriminate between groups of sub-
jects, and has shown accuracies up to 86–91% in the
correct distinction between patients with established
schizophrenia and healthy controls (Fan et al. 2008;
Sun et al. 2009). Although the application of SVM to
the classiﬁcation of patients and healthy controls
has validity in research, it has limited clinical utility
because the same or even better accuracy can be
achieved through clinical interview alone. A more
meaningful clinical application of these methods is in
helping the identiﬁcation of predictors of outcome.
These could help direct, to more vulnerable individ-
uals, the early implementation of targeted inter-
ventions that have been shown to reduce relapse
rates, such as optimized pharmacological treatment,
assertive case-management or family interventions,
resulting in better clinical and functional outcomes
(Malla et al. 2008; Larsen et al. 2011).
In this study, we applied SVM methods to MRI data
obtained at the ﬁrst episode of psychosis, and related
them to subsequent illness course type, to provide
novel, methodologically sound, proof of concept that
MRI can be used at illness onset to predict clinical
outcome. Outcome was evaluated on the basis of
having achieved symptom control, an important target
in the treatment of schizophrenia (Selten et al. 2007).
To our knowledge, this is not only the ﬁrst time that
SVM has been used in patients with psychosis to pre-
dict clinical outcome but also the ﬁrst time that it has
been applied to MRI scans obtained at the ﬁrst episode
of psychosis, and using a straightforward processing
pipeline of promise for application in clinical practice.
This application is challenging for classiﬁcation, as
the diﬀerences observed at the ﬁrst episode of psy-
chosis are likely to be much more subtle then those
observed in established schizophrenia (Ellison-Wright
et al. 2008). We predicted that patients with the poorest
course (continuously psychotic) could be disting-
uished both from those with the best course (episodic)
and from healthy individuals, with a signiﬁcant ac-
curacy. In a secondary, exploratory analysis we in-
vestigated whether the pattern that best distinguished
patients with a continuous course from those with
an episodic course could also correctly predict which
of the patients with an intermediate course would
have developed further illness episodes after the ﬁrst
one.
Method
We recruited a cohort of 100 patients at their ﬁrst
presentation to psychiatric services with a functional
psychotic illness (DSM-IV 295–298 psychotic codings;
APA, 1994) and 91 healthy individuals with the same
socio-economic background. The methods have been
extensively described elsewhere (Dazzan et al. 2004,
2008). Written informed consent was obtained from
all patients, and the study was approved by the local
research ethics committee. At ﬁrst presentation, we
interviewed patients using the World Health Organiz-
ation (WHO) Schedules for Clinical Assessment in
Neuropsychiatry (SCAN) and made a diagnosis ac-
cording to ICD-10 criteria (WHO, 1992a,b) by consen-
sus in meetings with senior clinicians from the
Institute of Psychiatry, in which all clinical infor-
mation was presented. A total symptomatology score
was obtained by summing the SCAN’s individual
symptom item scores according to the Wing & Sturt
(1978) procedure for the Present State Examination
(PSE; Wing et al. 1974; Wing & Sturt, 1978). This was
an appropriate model to adopt as the SCAN in-
corporates the 10th edition of the PSE. Information on
antipsychotic drug dose (in chlorpromazine equiv-
alents) and duration of exposure to antipsychotics was
collected during face-to-face interviews, from clinical
notes and from interviews with the clinical team.
Evaluation of outcome
Patients were re-evaluated 6.2 (S.D.=2.3) years later.
Information on illness course was obtained using an
amended version of the WHO Life Chart (Harrison
et al. 2001). This measure has been used successfully in
previous long-term follow-up studies, and has been
shown to be reliable in the assessment of clinical rat-
ings (Susser et al. 2000). We used the SCAN (WHO,
1992b) criteria to establish absence of psychotic symp-
toms during the follow-up period, in accordance with
WHO and other long-term outcome studies (Jablensky
et al. 1992). In line with Andreasen et al. (2005), we
used a 6-month period for establishing remission.
The operational criteria used in the study to deﬁne a
psychotic episode and remission are presented in the
Appendix. From the Life Chart, we used illness course
type as our primary clinical outcome measure. This
was deﬁned as either: continuous (no remission of
symptoms of greater than 6 months); episodic (one
or more period of remission of at least 6 months, and
no episode of psychosis, including the ﬁrst one, that
lasted for 6 months or more); or intermediate (never
achieved sustained periods of remission, but also
never experienced psychotic symptoms for prolonged
periods). We used a conservative approach for the
identiﬁcation of the pattern that best predicted
outcome, and only included in the ﬁrst stage of the
SVM analyses patients with either an episodic or a
continuous course, thought to best reﬂect good and
1038 J. Mourao-Miranda et al.poor clinical outcome respectively. In the second
stage, we used this pattern to classify the intermediate
patients and establish whether the pattern correctly
predicted the occurrence of further episodes in this
group, during the follow-up period.
Image processing
Images were acquired using a 1.5-T GE scanner
(General Electric Medical Systems, USA), at the
Maudsley Hospital, London. Tissue maps were pro-
duced from T1-weighted coronal images [1.5 mm slice
thickness, in-plane resolution 0.9374r0.9374 mm
2,
repetition time (TR) 13.8 ms, inversion time (TI)
450 ms, echo time (TE) 2.8 ms, and ﬂip angle 20x] using
SPM5 (Wellcome Department of Cognitive Neurology,
London, UK). Modulated plus warped [spatially
normalized to Montreal Neurological Institute (MNI)
space] gray-matter segments were created with a re-
sliced ﬁnal voxel size of 2r2r2m m
3, and ﬁnally
smoothed with an 8-mm isotropic full-width at half-
maximum (FWHM) Gaussian kernel.
Pattern classiﬁcation analysis
Data representation
The modulated, warped and smoothed gray-matter
images (probability maps) were used as input to the
SVM classiﬁer. A mask was applied including only
gray-matter voxels in common for all subjects (healthy
controls and patients with episodic, continuous or
intermediate course). To create a common mask, we
excluded voxels in the image that had a gray-matter
probability value equal to zero for at least one subject.
SVM classiﬁcation
The SVM is a pattern recognition approach that ﬁnds
a decision function or boundary that enables classiﬁ-
cation. It is based on statistical learning theory
(Vapnik, 1995) and has emerged as a powerful classi-
ﬁcation tool. The SVM classiﬁer is trained by provid-
ing examples of the form <x,c>where x represents
a spatial pattern (e.g. gray-matter image) and c is the
class label (e.g. c=+1 for patients and c=x1 for
healthy controls). In the context of pattern classiﬁ-
cation, each brain image corresponds to a point in the
input space, and each voxel in the image represents
one dimension of this space. A hypothetical example
of a classiﬁcation problem in two-dimensional space is
displayed in Fig. 1a. The gray circles represent images
of patients and the black circles represent images of
healthy controls. The dashed lines represent possible
separating hyperplanes. During the training phase, the
SVM ﬁnds the hyperplane or decision function that
separates the examples in the input space according to
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Fig. 1. The support vector machine (SVM) classiﬁer. (a) Illustration of a classiﬁcation problem between two groups
(patients versus controls) for the simpliﬁed case of only two voxels. Each brain image (e.g. gray-matter map) corresponds to a
point in the input space and each voxel in the image represents one dimension of this space. The gray circles represent the
images of patients and the black circles images of healthy controls. The dashed lines represent hyperplanes or decision
boundaries that separate the groups. (b) Illustration of the optimal hyperplane determined by the SVM algorithm. The optimal
hyperplane (dashed line) is the one with the largest margin of separation between the two classes or groups. The symbols at the
margin (circled) are the support vectors. During the training phase the SVM ﬁnds the optimal hyperplane or decision boundary.
During the test phase the decision boundary can be applied to classify new examples (white squares). The optimal hyperplane is
described by a weight vector and an oﬀ-set.
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decision function is determined from the training
data, it can be used to predict the group membership
of a new test example (e.g. white squares, Fig. 1b). The
optimal hyperplane is described by a weight vector
and an oﬀ-set. The weight vector is orthogonal to the
hyperplane and corresponds to the most discriminat-
ing direction between the groups. The weight vector
can be plotted as a brain image showing the relative
importance of the voxels in discriminating the classes.
In this study we exclusively used a linear kernel
SVM to reduce the risk of overﬁtting the data and
to allow direct extraction of the weight vector as an
image (the SVM discrimination map). The linear SVM
has only one parameter (C) that controls the trade-oﬀ
between having zero training errors and allowing
misclassiﬁcations. This was ﬁxed at C=1 for all cases
(default value). It has been shown previously that the
SVM performance for whole-brain classiﬁcation does
not change for a large range of C values and only de-
grades with very small C values (LaConte et al. 2005).
This is because there are more dimensions than ex-
amples (i.e. more voxels than brain scans). However,
in cases where the dimensionality of the data is smal-
ler than the number of examples (e.g. classiﬁcation
based on small regions of interest), it is necessary to
use a cross-validation procedure to ﬁnd the optimal C
value. The pattern classiﬁcation analyses were per-
formed using the PROBID toolbox (www.brainmap.
co.uk/probid.htm).
Cross-validation
We trained each classiﬁer independently (continuous
versus episodic, continuous versus healthy controls,
episodic versus healthy controls). Therefore, each con-
trast had a diﬀerent classiﬁer, only used in that
contrast. The performance of each classiﬁer was then
validated with the commonly used leave-two-out
cross-validation approach, which provides a relatively
unbiased estimate of the true generalization perform-
ance (Ecker et al. 2010). In each trial, observations from
all but one subject from each group were used to train
the classiﬁer. Subsequently, the class assignment of the
test subjects was calculated during the test phase. This
procedure was repeated S times (S=number of sub-
jects per group), each time leaving out observations
from a diﬀerent subject from each group. The accuracy
of the classiﬁer was estimated from the proportion
of images correctly classiﬁed in both groups, and
calculated as the average value of sensitivity and
speciﬁcity (percentage of test examples from both
classes correctly classiﬁed). The sensitivity and speci-
ﬁcity of the classiﬁer were deﬁned as: sensitivity=
TP/(TP+FN) and speciﬁcity=TN/(TN+FP), where
TP=true positives (proportion of images of group 1
correctly classiﬁed); TN=true negatives (proportion
of images of group 2 correctly classiﬁed); FP=false
positives (proportion of images of group 2 classiﬁed as
group 1); and FN=false negatives (proportion of
images of group 1 classiﬁed as group 2).
Permutation test
Permutation testing was used to derive a p value for
the accuracy of each classiﬁer. Here, we permuted the
class labels 1000 times (randomly assigning continu-
ous and episodic labels to the training subjects) and
repeated the cross-validation procedure. We then cal-
culated the number of times in which the speciﬁcity
(percentage of true negative) and sensitivity (per-
centage of true positive) for the permuted labels were
higher than those obtained for the real labels. Dividing
this number by 1000 we derived a p value for the
classiﬁcation accuracies.
Applying the SVM classiﬁer to a new sample
In the second stage, the classiﬁer obtained in the con-
tinuous versus episodic classiﬁcation was used to
classify patients with the intermediate course. In this
phase we explored whether these patients were
classiﬁed as continuous if they had developed further
episodes of illness after the ﬁrst one, or episodic if they
had not developed additional episodes.
Discriminating maps (SVM weight vector)
The SVM weight vector is a linear combination
or weighted average of the support vectors, that is
the training examples that are the most diﬃcult to
separate. The weight vector is therefore a spatial rep-
resentation of the decision boundary. Every voxel
contributes with a certain weight to the decision
boundary or classiﬁcation function. Given a positive
and a negative class (e.g. +1=episodic group,
x1=continuous group), a positive weight for a voxel
would indicate that the weighted average in that
voxel was higher, for example, for the episodic group,
whereas a negative weight would indicate that the
weighted average was higher for the continuous
group (Mourao-Miranda et al. 2005).
The SVM classiﬁers are multivariate techniques
(therefore, they take into account spatial correlations
in the data) and because the discrimination is based
on the whole brain pattern, rather than on individual
regions, all voxels contribute to the classiﬁcation and
no local inferences based on these approaches should
be made. We present a list of regions with relatively
higher contributions to the decision function or
classiﬁcation. We selected the peaks of the SVM
1040 J. Mourao-Miranda et al.weight vector for each classiﬁer, setting the threshold
value to 30% of the maximum (absolute) weight value,
and estimated the anatomical regions (cluster peaks)
that most contributed to the classiﬁer in the discrimi-
nation between groups.
Results
From the original cohort, 30 patients developed a
continuous course, 35 an episodic course, and 35 an
intermediate course. We excluded nine scans because
of poor image acquisition and/or motion artifact. In
the ﬁrst stage of the SVM analysis, we compared 28
subjects with a continuous course, 28 with an episodic
course, and 28 healthy volunteers [mean age 25.7
(S.D.=5.6) years; 14 males] of similar age. We then in-
cluded in the analysis 32 subjects with an intermediate
illness course type. Sociodemographic and clinical
characteristics of the patient groups are described
in Table 1. The mean duration of follow-up was 6.2
(S.D.=2.3) years. There were more subjects with a base-
line diagnosis of schizophrenia spectrum psychosis
(schizophrenia, schizophreniform disorder, schizo-
aﬀective disorder) in the continuous (71%) and inter-
mediate (66%) groups than in the episodic group
(43%, p=0.07). The diﬀerence increased further when
diagnosis was conﬁrmed at follow-up (continuous
86%, intermediate 75%, episodic 25%, p<0.01).
The ﬁrst stage of the SVM analysis showed that, at
baseline, patients with a future continuous course
could already be distinguished, with accuracies above
chance level, both from patients with a future episodic
course (accuracy=70%; 71% correctly classiﬁed as
continuous; p=0.004) and from healthy individuals
(accuracy=67%; 71% correctly classiﬁed as continu-
ous; p=0.01) (Table 2). By contrast, patients with an
episodic course were not signiﬁcantly distinguished
from healthy individuals (accuracy=54%).
The anatomical regions with the highest contribu-
tion to the discrimination of the continuous group
from the episodic and the healthy control groups
included the cingulate and parahippocampal gyri,
basal ganglia and thalami (Fig. 2, Tables 3 and 4).
In the second and ﬁnal stage of the analysis we
classiﬁed patients with an intermediate course ac-
cording to the discriminating pattern obtained in
the episodic versus continuous analysis. We found
that 78% of those who did not go on to develop
other episodes were classiﬁed as episodic, and 65% of
those who developed further episodes were classiﬁed
as continuous (sensitivity=65; speciﬁcity=78; ac-
curacy=72%; p=0.035). These results indicate that, as
expected, training the classiﬁer to discriminate the two
‘extreme’ groups (continuous versus episodic) ident-
iﬁes a pattern that provides information useful to
classify the remaining patients.
Discussion
To our knowledge, this is the ﬁrst study to investigate
whether spatially distributed information in brain
tissue data, obtained at the ﬁrst presentation of psy-
chosis, can potentially be used to predict subsequent
illness course type at the individual level. The study
provides proof of concept that MRI can be used as a
tool for the prediction of illness course. Our ﬁndings
Table 1. Sociodemographic and clinical characteristics of the patients included in the analyses
Episodic
(n=28)
Intermediate
(n=32)
Continuous
(n=28) p value
Gender (% males) 50 67 75 N.S.
Age (years) 26.5¡25.9 25.9¡8.5 28.8¡10 N.S.
Education (years) 13.9¡2.5 12.2¡2.2 12¡2.1 0.002
Ethnicity (% White British) 50 41 39 N.S.
Baseline diagnosis (% schizophrenia)a 43 66 71 0.07
Follow-up diagnosis (% schizophrenia)a 25 75 86 <0.001
Antipsychotic dose (chlorpromazine equivalents, mg)b 136¡170 197¡205 180¡212 N.S.
Time on antipsychotics up to MRI (weeks)c 4.9¡8 10.7¡10 6.9¡10 0.07
Total symptom severity at baseline 30.5¡19 32.1¡19 33.2¡19 N.S.
Total gray and white-matter volume (liters) 1.14¡0.1 1.11¡0.1 1.1¡0.1 N.S.
MRI, Magnetic resonance imaging; N.S., not signiﬁcant.
Values given as percentage or mean ¡ standard deviation.
aChange in diagnosis over follow-up does not simply reﬂect an increase in one diagnostic group and a decrease in another
one, but a change in both directions, with approximately 45% of patients changing diagnosis at follow-up.
bInformation missing for nine subjects.
cInformation missing for 10 subjects.
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who will subsequently develop a continuous illness
course may be already distinguished, above chance
level, from those who will develop an episodic course,
using a classiﬁer trained only on patient groups. By
contrast, patients with a future episodic course cannot
be distinguished from healthy individuals. Finally,
our ﬁndings provide preliminary evidence that, even
for patients with a ‘less extreme’ (or intermediate)
type of outcome, it is possible to predict, to a certain
extent, who will develop further episodes and who
will be less likely to do so.
Although signiﬁcant, the accuracy with which we
have correctly classiﬁed patients is lower than that
reported in other studies that have used SVM
(Fan et al. 2008; Sun et al. 2009). Of note, these studies
have applied SVM to patients with an established
illness, rather than at ﬁrst episode, and have used SVM
to deﬁne subject status (patient versus control) rather
than future illness course. It is possible that, as more
marked and distributed brain changes occur with ill-
ness progression (Ellison-Wright et al. 2008), the classi-
ﬁcation and distinction between patients and healthy
individuals becomes more accurate in later illness
stages. Interestingly, a study that applied SVM to the
early detection of diﬀerent at-risk mental states for
subthreshold psychotic symptoms reported accuracies
lower than those reported in patients with established
Table 2. Results of the support vector machine (SVM) classiﬁcation
Comparison Sensitivity Speciﬁcity Accuracy p
Continuous versus episodic 71 68 70 0.004
Continuous versus healthy individuals 71 61 67 0.01
Episodic versus healthy individuals 64 43 54 0.3
The results are give for the SVM classiﬁcation in two classes: ratio of true positive (sensitivity), true negative (speciﬁcity),
accuracy and statistical probability. The ﬁrst column shows the groups of subjects considered in each classiﬁcation. The second
column shows the percentage of subjects in the ﬁrst group correctly classiﬁed as pertaining to it (sensitivity). The third column
shows the percentage of subjects in the second group correctly classiﬁed as non-pertaining to the ﬁrst group (speciﬁcity). The
fourth column shows the accuracy (arithmetic mean between sensitivity and speciﬁcity). The last column shows the statistical
probability that the result has been obtained by chance. It was obtained after 1000 permutations within the subjects. The number
of subjects considered in each classiﬁcation was 56 (28 in each group).
1.00
0.66
0.33
0.05
–0.05
–0.33
–0.66
–1.00
Continuous v. Episodic
Continuous v. Controls
Fig. 2. Discrimination map or support vector machine (SVM) weight vector: continuous versus episodic course (top), continuous
course versus healthy individuals (bottom). The colours represent the weight of each voxel in the classiﬁcation function
(the red scale represents positive weights and the blue scale represents negative weights). The SVM weight vector is a linear
combination or weighted average of the support vectors, that is the training examples that are most diﬃcult to separate and
deﬁne the decision boundary. The weight vector is therefore a spatial representation of the decision boundary. Every voxel
contributes with a certain weight to the decision boundary or classiﬁcation function. Given a positive and a negative class
(e.g. +1=episodic group; x1=continuous group), a positive weight for a voxel means the weighted average in that voxel was
higher for the episodic group, and a negative weight means the weighted average was higher for the continuous group. Because
the classiﬁer is multivariate by nature, the combination of all voxels as a whole is identiﬁed as a global spatial pattern by
which the groups diﬀer (the discriminating pattern). Therefore, the discrimination map should not be interpreted as a standard
statistical parametric map resulting from a mass-univariate statistical test to ﬁnd group diﬀerences, and no local inferences
should be made based on the SVM weights.
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with our ﬁnding, a study that used a diﬀerent classi-
ﬁcation approach to predict 1-year outcome in ﬁrst-
episode psychosis patients also reported an accuracy
similar to the one we observed (Kasparek et al. 2011).
Nevertheless, the better classiﬁcation we found in in-
dividuals destined to develop a continuous illness
course suggests that signiﬁcant brain changes have
already occurred by the time of ﬁrst contact in this
subgroup.
Although, with these methods, it is not possible to
make local inferences on the discriminating regions,
it is noteworthy that the anatomical regions with the
highest contribution to the discrimination between
groups include the cingulate and parahippocampal
gyri, the basal ganglia and the thalami, which have
been consistently reported as important in the
pathophysiology of schizophrenia (Ellison-Wright
et al. 2008).
Our study should be taken as preliminary, but it
proposes a promising approach for the future trans-
lation of imaging into patient beneﬁt. Although our
approach requires replication and validation in a lar-
ger sample, it provides initial evidence of an easy and
accessible methodology that could potentially enable
rapid clinical decisions. We believe that future devel-
opment should consider that, although a better classi-
ﬁcation accuracy could potentially be achieved with
feature selection approaches preceding the SVM clas-
siﬁer, this would involve applying cross-validation
pipelines that are time-consuming, calculation inten-
sive and/or methodologically challenging. Such
approaches can be useful in the research setting but
might not enable a rapid and user-friendly assessment
Table 3. List of the most discriminating regions (cluster peaks) for the classiﬁer episodic versus continuous
Regions x y z
Cluster volume
(mm
3)
Peak
value
Positive weights
Right caudate nucleus 18.8 4.9 16.9 770 17.045
Left caudate nucleus x19.8 13.8 12 88 14.899
Left putamen x20.8 1.9 13.9 140 15.235
Right putamen 29.7 x8 3.1 130 8.5717
Substantia nigra 9.9 x15.9 x12.8 426 11.502
Right globus pallidus 25.7 x13 x3.9 98 9.9449
Right anterior cingulate cortex (BA 25) 5.9 11.8 x10.8 324 10.65
Right parahippocampal gyrus (BA 30, BA 27) 15.8 x41.7 6 330 13.916
20.8 x34.8 x3.9 105 9.8681
Left parahippocampal gyrus (BA 30, BA 28, BA 34) x19.8 x36.7 5 173 16.723
x16.8 x11 x11.8 86 8.2407
x23.7 0.9 x10.8 56 10.665
Negative weights
Left caudate nucleus x16.8 x23.9 27.8 491 x12.158
Right caudate nucleus 18.8 1.9 22.8 186 x19.143
Left putamen x27.7 x18.9 x5.8 81 x11.904
Right putamen 29.7 x14 x7.8 85 x10.77
Right globus pallidus 11.9 x7 x7.8 85 x9.2672
Right anterior cingulate gyrus (BA 24) 9.9 x1.1 33.7 329 x15.372
Left anterior cingulate gyrus (BA 24) 0 x7 22.8 91 x11.821
Left posterior cingulate gyrus (BA 29) x4 x41.7 17.9 53 x9.1322
Right posterior cingulate gyrus (BA 23) 2 x23.9 26.8 181 x10.48
Left parahippocampal gyrus (BA 27, BA 35) x19.8 x33.8 x3.9 97 x13.182
x22.7 x28.8 x11.8 137 x9.364
Left amygdala x26.7 x9 x11.8 114 x10.084
Right amygdala 27.7 x7 x11.8 279 x12.003
Hypothalamus x6.9 x3.1 x10.8 69 x11.211
Left cerebellum x15.8 x41.7 x16.7 188 x9.8005
Right cerebellum 5.9 x41.7 x10.8 351 x11.505
x, y, z are Talairach coordinates of the cluster peaks selected using 3Dclust in AFNI (http://afni.nimh.nih.gov/afni). The
regions were estimated using the software Talairach Client (www.talairach.org/).
Prediction of illness course at ﬁrst psychotic episode 1043of patients’ prognosis. Furthermore, there is at present
no conclusive evidence that feature selection increases
the accuracy for MRI-based diagnosis, while sub-
stantially increasing computation time without im-
proving classiﬁcation performance (Cuingnet et al.
2011). Therefore, we have preferred here a whole brain
approach, which has stronger potential for future
applicability in the clinical setting. Once the SVM
classiﬁer is trained and a decision function is gener-
ated, a new example could be classiﬁed in minutes.
The pipeline we used includes pre-processing of
the structural images using standard neuroimaging
software (SPM), extraction of a feature vector contain-
ing gray-matter values, and application of the SVM
decision function to the feature vector. Moreover, the
greater the complexity of the method (i.e. the number
of steps in the pipeline), the greater the danger of
overﬁtting the data. By contrast, maintaining a simple
pipeline improves the translational potential of the
method, as such a technique will be more likely to be
incorporated into routine clinical investigations, be-
cause a structural MRI can be obtained in 10 minutes.
In psychiatry, clinicians do not have algorithms to
quantify the risk of, for example, occurrence of further
episodes, which could help in guiding clinical de-
cisions. Such algorithms are of common use in other
areas of medicine, such as heart medicine and on-
cology. Our results oﬀer preliminary evidence that,
once further developed and validated, an SVM ap-
proach could in the future be used by a psychiatrist to
say, for example, that on the basis of the MRI scan,
a patient may have 88% probability of having more
illness episodes (positive predictive value: in this ex-
ample, it is calculated as the proportion of intermedi-
ate subjects who went on to experience repeated
episodes and who were classiﬁed as continuous by the
Table 4. List of the most discriminating regions (cluster peaks) for the classiﬁer continuous versus healthy individuals
Regions x y z
Cluster volume
(mm
3)
Peak
value
Positive weights
Right caudate nucleus 19.8 4.9 19.9 660 16.11
Left pulvinar x19.8 x35.8 2.1 581 12.659
Right pulvinar 10.9 x28.8 10 552 15.777
Left putamen x18.8 2.9 13.9 210 14.144
Right putamen 22.7 11.8 x2.9 121 8.363
Left lateral globus pallidus x24.7 x9 x2.9 164 12.189
Right thalamus 2 x13 15.9 432 9.8022
23.7 x20.9 7 145 15.65
Left red nucleus x3 x22.9 x4.8 310 10.292
Right parahippocampal gyrus (BA30, BA28) 16.8 x40.7 5 282 14.279
x15.8 x6 x10.8 161 10.278
Left parahippocampal gyrus (BA30) x15.8 x35.8 x6.8 61 8.3901
Right anterior cingulate gyrus (BA24) 11.9 27.7 x2.9 229 16.131
Right posterior cingulate gyrus (BA 23) 5.9 x20.9 22.8 78 14.808
Left cerebellum x5.9 x35.8 2.1 57 9.5645
Negative weights
Left caudate nucleus x4 12.8 13 722 x11.528
Right caudate nucleus 18.8 x23.9 22.8 153 x9.527
Left putamen x19.8 14.8 x2.9 500 x10.024
Right putamen 27.7 x22.9 1.1 243 x13.137
Left pulvinar x13.8 x34.8 16.9 99 x13.191
Right pulvinar 21.8 x27.8 9 124 x21.096
Right globus pallidus 20.8 x10 8 64 x8.4599
Hypothalamus x6.9 x3.1 x9.8 189 x9.0975
Left anterior cingulate gyrus (BA24) x1 x3.1 27.8 107 x11.888
Right anterior cingulate gyrus (BA24) 12.9 x4 32.7 154 x15.651
Parahippocampal gyrus (BA 25, BA28) x21.8 x16.9 x9.8 517 x15.527
x15.8 x22.9 x21.7 55 x7.2935
Cerebellum 6.9 x42.7 x10.8 1795 x13.963
x, y, z are Talairach coordinates of the cluster peaks selected using 3Dclust in AFNI (http://afni.nimh.nih.gov/afni). The
regions were estimated using the software Talairach Client (www.talairach.org/).
1044 J. Mourao-Miranda et al.SVM classiﬁer), thus providing more information on
which to base therapeutic decisions. This would imply
applying risk quantiﬁcation in psychiatry, something
that has not yet been achieved. Furthermore, the
quantiﬁcation could improve even further and be re-
ﬁned if other factors related to outcome, such as dur-
ation of untreated psychosis, were taken into account
in a decision tree.
As mentioned earlier, our study is preliminary and
the ﬁndings should be considered with caution. An
important limitation is the relatively small sample
size. In addition, future work should consider vali-
dating the accuracy of our classiﬁer with an indepen-
dent larger sample of patients classiﬁed according to
the same illness course criteria. Finally, as this study
used data from a single site, it remains unclear to what
extent diﬀerences in acquisition protocol or scanners
aﬀect the accuracy of the classiﬁer. Nevertheless, it is
encouraging that the classiﬁer trained in using the two
extremes groups of patients (i.e. episodic versus con-
tinuous) could be successfully applied to classify the
intermediate group of patients. Future studies with
multi-site images will allow an investigation of the
extendibility of the approach to images from diﬀerent
sites.
Ultimately, once developed, these methods could
allow a patient to be assigned to targeted assertive
case-management at ﬁrst presentation to services, with
optimized pharmacological treatment, cognitive and
family interventions, which have been shown to im-
prove treatment adherence and reduce relapse rates
(Malla et al. 2008; Eack et al. 2010), eventually im-
proving outcome. At the same time, those patients
most likely to have a good remitting illness after their
ﬁrst episode could avoid long-term exposure to anti-
psychotic medication. We propose that, with further
development and validation on larger datasets, a
simple and automated SVM pipeline oﬀers a promis-
ing approach to help rapid and early clinical decisions
based on imaging data, which will eventually beneﬁt
patient care and reduce health-care costs.
Appendix
The operational deﬁnition of a ‘psychotic episode’
A psychotic episode is a period of symptomatology in
which the presence of at least one of the following
symptoms can be ascertained:
Group A
1. Hallucinations or pseudo-hallucinations in any
modality.
2. Delusions.
3. Marked thought and speech disorder (e.g. incoher-
ence, irrelevance, thought blocking, neologisms,
incomprehensibility of speech) other than simple
retardation or acceleration.
4. Marked psychomotor disorder (e.g. negativism,
mutism or stupor, catatonic excitement, con-
strained attitudes or unnatural postures maintained
for long periods) other than simple retardation or
acceleration.
5. Emergence or marked exacerbation of bizarre and
grossly inappropriate behavior (e.g. talking or
giggling to self, acts incomprehensible to others,
loss of social constraints, etc.).
A psychotic episode may be considered as present also
in the absence of the manifest symptoms listed in
Group A if at least two of the following behaviors have
emerged or become markedly exacerbated:
Group B
1. Marked reduction or loss of interest, initiative
and drive, leading to serious deterioration of the
performance of usual activities and tasks.
2. Emergence or marked exacerbation of social with-
drawal (active avoidance of communication with
other people).
3. Severe excitement, purposeless destructiveness or
aggression.
4. Episodic or persistent states of overwhelming fear
or severe anxiety.
5. Gross and persistent self-neglect.
The operational deﬁnition of a ‘remission’
A remission is a state following a psychotic episode, in
which none of the symptoms listed as characteristics
of a psychotic episode are present. During a remission
a patient may exhibit a variety of non-psychotic symp-
toms (e.g. depressed mood, neurotic manifestations)
or some of the so-called negative symptoms, or be
entirely symptom free (incomplete or complete re-
mission). A rating of remission (and also a rating of a
psychotic episode) should be based only on the ascer-
tainable absence (or presence) of psychotic symptoms
and not on whether or not the patient is taking any
psychotropic medication or whether or not he/she
is hospitalized. The absence of psychotic symptoma-
tology would qualify as a remission only if it lasts for
6 months.
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